The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[alpinumisoflavone results in increased expression of FAS protein] which results in increased cleavage of CASP3 protein alpinumisoflavone results in increased cleavage of CASP3 protein
alpinumisoflavone results in increased cleavage of CASP9 protein [alpinumisoflavone results in increased expression of FAS protein] which results in increased cleavage of CASP9 protein
[alpinumisoflavone results in increased expression of FAS protein] which results in increased cleavage of CASP3 protein; [alpinumisoflavone results in increased expression of FAS protein] which results in increased cleavage of CASP9 protein
alpinumisoflavone inhibits the reaction [1,10-phenanthroline deficiency results in increased activity of HIF1A protein]; alpinumisoflavone inhibits the reaction [Oxygen deficiency results in increased activity of HIF1A protein]
auriculasin affects the localization of AIFM1 protein [TNFSF10 protein co-treated with auriculasin] affects the localization of AIFM1 protein; TNFRSF10B protein affects the reaction [[TNFSF10 protein co-treated with auriculasin] affects the localization of AIFM1 protein]
[TNFSF10 protein co-treated with auriculasin] results in decreased phosphorylation of AKT1 protein; auriculasin inhibits the reaction [VEGFA protein results in increased phosphorylation of AKT1 protein]
[auriculasin co-treated with TNFSF10 protein] results in increased expression of BAX protein; TNFRSF10B protein affects the reaction [[auriculasin co-treated with TNFSF10 protein] results in increased expression of BAX protein]
auriculasin results in decreased expression of BCL2 protein [auriculasin co-treated with TNFSF10 protein] results in decreased expression of BCL2 protein; TNFRSF10B protein affects the reaction [[auriculasin co-treated with TNFSF10 protein] results in decreased expression of BCL2 protein]
[auriculasin co-treated with TNFSF10 protein] results in increased expression of CASP3 protein; TNFRSF10B protein affects the reaction [[auriculasin co-treated with TNFSF10 protein] results in increased expression of CASP3 protein]
[auriculasin co-treated with TNFSF10 protein] results in increased expression of CASP8 protein; TNFRSF10B protein affects the reaction [[auriculasin co-treated with TNFSF10 protein] results in increased expression of CASP8 protein]
[auriculasin co-treated with TNFSF10 protein] results in increased expression of CASP9 protein; TNFRSF10B protein affects the reaction [[auriculasin co-treated with TNFSF10 protein] results in increased expression of CASP9 protein]
CYP2C19 protein results in increased metabolism of auriculasin Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of auriculasin]
CYP2C8 protein results in increased metabolism of auriculasin Quercetin inhibits the reaction [CYP2C8 protein results in increased metabolism of auriculasin]
[TNFSF10 protein co-treated with auriculasin] results in increased expression of DDIT3 protein; TNFRSF10B protein affects the reaction [[TNFSF10 protein co-treated with auriculasin] results in increased expression of DDIT3 protein] auriculasin results in increased expression of DDIT3 protein
[TNFSF10 protein co-treated with auriculasin] results in decreased phosphorylation of MTOR protein; auriculasin inhibits the reaction [VEGFA protein results in increased phosphorylation of MTOR protein]
[auriculasin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; TNFRSF10B protein affects the reaction [[auriculasin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]
[auriculasin co-treated with TNFSF10 protein] affects the expression of CASP10 protein; [auriculasin co-treated with TNFSF10 protein] results in decreased expression of BCL2 protein; [auriculasin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [auriculasin co-treated with TNFSF10 protein] results in increased expression of BAX protein; [auriculasin co-treated with TNFSF10 protein] results in increased expression of CASP3 protein; [auriculasin co-treated with TNFSF10 protein] results in increased expression of CASP8 protein; [auriculasin co-treated with TNFSF10 protein] results in increased expression of CASP9 protein; [TNFSF10 protein co-treated with auriculasin] affects the localization of AIFM1 protein; [TNFSF10 protein co-treated with auriculasin] affects the localization of ENDOG protein; [TNFSF10 protein co-treated with auriculasin] results in decreased phosphorylation of AKT1 protein; [TNFSF10 protein co-treated with auriculasin] results in decreased phosphorylation of MTOR protein; [TNFSF10 protein co-treated with auriculasin] results in increased expression of DDIT3 protein; [TNFSF10 protein co-treated with auriculasin] results in increased expression of TNFRSF10B protein; [TNFSF10 protein co-treated with auriculasin] results in increased expression of TP53 protein; TNFRSF10B protein affects the reaction [[auriculasin co-treated with TNFSF10 protein] results in decreased expression of BCL2 protein]; TNFRSF10B protein affects the reaction [[auriculasin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; TNFRSF10B protein affects the reaction [[auriculasin co-treated with TNFSF10 protein] results in increased expression of BAX protein]; TNFRSF10B protein affects the reaction [[auriculasin co-treated with TNFSF10 protein] results in increased expression of CASP3 protein]; TNFRSF10B protein affects the reaction [[auriculasin co-treated with TNFSF10 protein] results in increased expression of CASP8 protein]; TNFRSF10B protein affects the reaction [[auriculasin co-treated with TNFSF10 protein] results in increased expression of CASP9 protein]; TNFRSF10B protein affects the reaction [[TNFSF10 protein co-treated with auriculasin] affects the localization of AIFM1 protein]; TNFRSF10B protein affects the reaction [[TNFSF10 protein co-treated with auriculasin] results in increased expression of DDIT3 protein]; TNFRSF10B protein affects the reaction [[TNFSF10 protein co-treated with auriculasin] results in increased expression of TNFRSF10B protein]; TNFRSF10B protein affects the reaction [[TNFSF10 protein co-treated with auriculasin] results in increased expression of TP53 protein]
[TNFSF10 protein co-treated with auriculasin] results in increased expression of TP53 protein; TNFRSF10B protein affects the reaction [[TNFSF10 protein co-treated with auriculasin] results in increased expression of TP53 protein]
auriculasin inhibits the reaction [VEGFA protein results in increased activity of and results in increased phosphorylation of KDR protein]; auriculasin inhibits the reaction [VEGFA protein results in increased phosphorylation of AKT1 protein]; auriculasin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK1 protein]; auriculasin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK3 protein]; auriculasin inhibits the reaction [VEGFA protein results in increased phosphorylation of MTOR protein]; auriculasin inhibits the reaction [VEGFA protein results in increased phosphorylation of SRC protein] auriculasin results in decreased expression of VEGFA protein
[[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP3 protein; [[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP9 protein; [[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein
cajanol results in decreased expression of BCL2 protein [[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP3 protein; [[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP9 protein; [[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein
[[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP3 protein cajanol results in increased activity of CASP3 protein
[[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP9 protein cajanol results in increased activity of CASP9 protein
cajanol affects the localization of CYCS protein [[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP3 protein; [[[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein] which results in increased activity of CASP9 protein; [[cajanol results in decreased expression of BCL2 protein] co-treated with [cajanol results in increased expression of BAX protein]] affects the localization of CYCS protein
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased chemical synthesis of Oxygen]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of and results in increased activity of NOS3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]
[afimoxifene binds to and results in decreased activity of ESR1 protein] which results in decreased susceptibility to Equol; [fulvestrant binds to and results in decreased activity of ESR1 protein] which results in decreased susceptibility to Equol; Equol binds to and results in increased activity of ESR1 protein; Estradiol affects the reaction [Equol affects the activity of ESR1 protein] Equol results in increased expression of ESR1 mRNA; Equol results in increased expression of ESR1 mRNA alternative form Equol results in increased activity of ESR1 protein Equol binds to ESR1 protein
Equol binds to and results in increased activity of ESR2 protein; Equol inhibits the reaction [KAT5 protein results in decreased activity of ESR2 protein]; Equol inhibits the reaction [KAT5 protein results in increased activity of ESR2 protein]; Estradiol affects the reaction [Equol affects the activity of ESR2 protein] Equol results in increased activity of ESR2 protein Equol binds to ESR2 protein
Equol inhibits the reaction [KAT5 protein results in decreased activity of ESR2 protein]; Equol inhibits the reaction [KAT5 protein results in increased activity of ESR2 protein]
[AG 1879 results in decreased activity of SRC protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]; [U 0126 results in decreased phosphorylation of [MAPK1 protein co-treated with MAPK3 protein]] which results in decreased susceptibility to Equol; AG 1879 inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]; Equol results in increased activity of and results in increased phosphorylation of MAPK1 protein; Pertussis Toxin inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Equol results in increased activity of and results in increased phosphorylation of MAPK1 protein]
[AG 1879 results in decreased activity of SRC protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]; [U 0126 results in decreased phosphorylation of [MAPK1 protein co-treated with MAPK3 protein]] which results in decreased susceptibility to Equol; AG 1879 inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]; Equol results in increased activity of and results in increased phosphorylation of MAPK3 protein; Pertussis Toxin inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Equol results in increased activity of and results in increased phosphorylation of MAPK3 protein]
[AG 1879 results in decreased activity of SRC protein] inhibits the reaction [Equol results in increased activity of and results in increased phosphorylation of NOS3 protein]; [Equol results in increased chemical synthesis of Superoxides] which results in increased activity of and results in increased phosphorylation of NOS3 protein; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of and results in increased activity of NOS3 protein]; Equol inhibits the reaction [NOS3 protein binds to CAV1 protein]; Equol results in increased activity of and results in increased phosphorylation of NOS3 protein; Equol results in increased phosphorylation of and results in increased activity of NOS3 protein; Manganese inhibits the reaction [Equol results in increased activity of and results in increased phosphorylation of NOS3 protein]; Pertussis Toxin inhibits the reaction [Equol results in increased activity of and results in increased phosphorylation of NOS3 protein]; Rotenone inhibits the reaction [Equol results in increased phosphorylation of and results in increased activity of NOS3 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Equol results in increased chemical synthesis of Superoxides] which results in increased phosphorylation of NOS3 protein]
Equol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; Equol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]
[AG 1879 results in decreased activity of SRC protein] inhibits the reaction [Equol results in increased activity of and results in increased phosphorylation of NOS3 protein]; [AG 1879 results in decreased activity of SRC protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]; [AG 1879 results in decreased activity of SRC protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]
glabridin results in increased expression of BAX protein [glabridin co-treated with Paclitaxel] results in increased expression of BAX protein Acetylcysteine inhibits the reaction [glabridin results in increased expression of BAX protein]; AKT activator SC79 inhibits the reaction [glabridin results in increased expression of BAX protein]
Acetylcysteine inhibits the reaction [glabridin results in decreased expression of BCL2 protein]; AKT activator SC79 inhibits the reaction [glabridin results in decreased expression of BCL2 protein] [glabridin co-treated with Paclitaxel] results in decreased expression of BCL2 protein
Acetylcysteine inhibits the reaction [glabridin results in increased activity of CASP3 protein]; AKT activator SC79 inhibits the reaction [glabridin results in increased activity of CASP3 protein]
glabridin results in increased cleavage of CASP9 protein [glabridin co-treated with Paclitaxel] results in decreased expression of CASP9 protein; [glabridin co-treated with Paclitaxel] results in increased cleavage of CASP9 protein
glabridin inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of TYR protein]; glabridin inhibits the reaction [alpha-MSH results in increased activity of TYR protein]
[Gemcitabine co-treated with licoricidin] results in decreased phosphorylation of AKT1 protein; [licoricidin co-treated with Gemcitabine] results in decreased phosphorylation of AKT1 protein licoricidin results in decreased phosphorylation of AKT1 protein
licoricidin promotes the reaction [Gemcitabine results in increased activity of CASP3 protein]; licoricidin promotes the reaction [Gemcitabine results in increased expression of and results in increased activity of CASP3 protein]; licoricidin results in increased expression of and results in increased activity of CASP3 protein licoricidin results in increased activity of CASP3 protein
licoricidin inhibits the reaction [Gemcitabine results in increased phosphorylation of RELA protein] licoricidin results in decreased phosphorylation of RELA protein
browse the term
